Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy

Yuanjun Lu, Yau-Tuen Chan, Hor-Yue Tan, Sha Li, Ning Wang* and Yibin Feng*

Abstract

Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response.

Keywords: Epigenetic modification, Cancer, Epi-drugs, Combination strategy, Tumour microenvironment

Introduction

The term “epigenetics” was addressed initially as “the branch of biology which studies the causal interactions between genes and their products, which bring the phenotype into being” by C.H. Waddington in the 1940s [1]. From then on, implications of epigenetics have been extended to a wide range of biological processes over time as accumulating evidence suggested that heritable changes to the genome occur independently of alterations in somatic cells regardless of their differentiation status [2]. The heritable changes, either occurring or maintaining during multiple cellular biological processes with the same genetic information, require fine-tuned epigenetic modifications, which commonly include DNA methylation, histone, or chromatin post-translational modifications (PTM), as well as non-coding RNAs regulations. Failure of heritability of epigenetic marks may result in inappropriate initiation or inhibition of gene expressions and lead to pathological changes, including cancers [3, 4].

Cancer is a consequence of accumulative genetic mutations in concert with epigenetic alterations, as well as environmental factors. A large number of studies have been taking great efforts in characterizing the genomic landscape of cancers from oncogene-driven signalling pathways to the mutation spectrum in different cancer subtypes. Distinct from genetic mutation, epigenetic influences refer to modifying gene expression without permanent changes in the genomic sequence. They are preferentially applied in cancer cells given that epigenetic alterations are reversible and faster regulated compared to genomic evolution [5]. Except for the fundamental changes that occur to the somatic cells, other multiple forces are cohesively shaping the landscape of cancer, thus bringing into additional dimensional complexity. The tumour microenvironment (TME) consists of supporting texture and cells and establishes a niche to fuel tumour cells with a multitude of stromal factors. Current epigenetic modifications are not only focused on the progress of cancer cells development, but also the tumour cells-TME interactions.

Given the importance of epigenetic regulation in cancers, the treatment targeting epigenetics is becoming an attractive strategy of cancer therapy. Epigenetic treatment
may therefore benefit cancer patients as monotherapy and a combinatory treatment with other current therapy. In this review, we summarize the mechanisms of epigenetic modifications in tumorigenesis, and we also envision more advanced sequencing technologies that would be available for epigenome mapping and enable epigenetic modifications precisely applied in cancer therapy. The drawback and potential pitfall of current epigenetic drugs are also discussed. We hope our review could shed light on the significance of epigenetics in the development and treatment of cancer.

**Mechanisms of epigenetic modifications**

The epigenetic modifications can be generally categorized into three groups: DNA and RNA methylations, histone modifications, and non-coding RNAs, which are considered as main mechanisms of regulation during carcinogenesis/cancer progression.

**DNA and RNA methylations**

**DNA methylation and demethylation**

DNA methylation is the most extensively studied epigenetic mechanism that predominantly occurs in CpG islands (CGIs) where preferentially located at the 5′ promoter region of more than 50% of human genes [6, 7]. It displays a fundamental function in development and diseases, including X chromosome inactivation, genomic imprinting, epigenetic reprogramming, cell identity establishment, and lineage specification [8–10]. Generally, it exhibits gene silencing via covalent addition of methyl groups from S-adenosylmethionine (SAM) to the 5 position of the cytosine pyrimidine ring. The 5-methylcytosine (m5C) structure can either prevent access of transcriptional factors (TFs) to the binding sites of DNA, or recruit methyl-binding domain proteins (MBDs) in association with histone modifications to reconfigure chromatin, thus leading topressive gene expression.

Three DNA methyltransferases (DNMTs), namely DNMT1, DNMT3a, and DNMT3b, are orchestrated in catalysing DNA methylation. DNMT1, the maintenance DNA methyltransferase, has a higher catalytic activity to preferentially methylate hemimethylated DNA during replication and is mostly responsible for maintaining the DNA methylation status [11, 12]. While the precise DNA methylation status in the genome is generated and supported by “de novo” methyltransferases, DNMT3a and DNMT3b, they display equal preference to bind to the previously unmethylated DNA independently of replication [13].

In contrast, DNA demethylation is a reverse action that recovers silenced genes affected by DNMTs. It is catalysed by a family of Ten-eleven translocation methylcytosine dioxygenases (e.g., TET1, TET2, and TET3), which can turn 5mC to 5-hydroxymethylcytosine (5-hmC), even further oxidize 5-hmC into 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC) [14, 15]. Homeostasis between the demethylation and methylation of the genome incurs as a dynamic mechanism of gene expression in various types of cells.

**RNA methylation**

N6-methyladenosine (m6A), referring to the methylation of adenosine residue at the N-6 position, was first discovered in the 1970s and is emerging as a hotspot issue in epigenetic mechanisms, as well as in cancer biology. M6A modification enriches near the stop codon, 3′UTR, and within internal long exons [16, 17]. It affects almost every aspect of RNA processing, including RNA transcription, degradation, splicing, and translation [18].

Recent studies have found that m6A modifications are reversible and dynamic. RNA m6A formation requires multiple methyltransferase components categorized as “writers”, including methyltransferase-like 3 (METTL3), METTL14, METTL16, Wilms tumour 1-associated protein (WTAP), RNA binding motif protein (RMB15/15B), zinc finger CCCH-type containing 13 (ZC3H13), and KIAA1429 [19–23]. While decoding of m6A methylation can be achieved by interactions among components of “erasers” (e.g. FTO and ALKBH5) and “readers”, such as YT521-B homology (YTH) domain-containing proteins, eukaryotic initiation factor 3 (eIF3), heterogenous nuclear ribonucleoprotein (HNRNP) protein family, and insulin-like growth factor 2 mRNA binding proteins (IGF2BP) family [24–27].

**Histone modifications**

In chromatin, DNA is packaged into a highly compact structure wrapped with histone octamer, thereby forming nucleosomes and the so-called “beads on a string” structure, which facilitate controlling the accessibility of DNA sequence. Each histone octamer is composed of a tetramer of two copies of histone 2A (H2A) and two copies of histone 2B (H2B), flanked by dimers of histone 3 (H3) and histone 4 (H4). These histone proteins contain a globular C-terminal domain and an extended N-terminal tail, which are subject to various PTMs, including methylation, acetylation, ubiquitylation, phosphorylation, SUMOylation, ADP ribosylation, citrullination, and biotinylation at specific amino acidic residues.

Among those PTMs, acetylation, and methylation of lysine residues on H3 and H4 have been mostly studied. The mechanism of histone acetylation is based on the “charge neutralization model” that the positive charge of lysine residues on H3/H4 facilitates a tight packaging of negatively charged DNA with histones. Whereas the addition of an acetyl group can lose up the tight configuration of chromatin, thus enabling transcriptional factors
(TFs) access for transcription [28]. Multiple enzymes are responsible for catalysing the addition and removal of acetyl groups, including histone acetyltransferases (HATs) and histone deacetylases (HDACs) respectively.

Unlike histone acetylation, the effect of histone methylation is more complicated and dependent on the targeted residues. For example, methylation at lysine 4/36/79 of histone H3 (H3K4/36/79) typically contributes to active transcriptional status, while methylation at H3K9/27 and H4K20 is generally considered to be repressive epigenetic marks [29–32]. They are exclusively catalysed by different histone methyltransferases (HMTs) that most of them contain a SET domain. For example, enhancer of zeste 2 (EZH2) is specific for H3K27 trimethylation (H3K27me3) that exerts transcriptional silencing function [33]. SET7/9 catalyses H3K4me that activates the expression of inflammatory genes [34]. Reversely, removing methyl groups from those marks by histone demethylases (HDMTs) also alters the status of transcriptional activity.

Non-coding RNAs
Non-coding RNAs (ncRNAs) take up more than 70% of human genome and have regulatory effects [35]. They are mainly categorized into small ncRNAs (snRNAs, < 200 nt) and long ncRNAs (lncRNAs, > 200 nt) based on size. The most characterized snRNA is miRNA, a highly conserved single-stranded RNA with ~ 20 nucleotides. They were considered as “junk transcripts” upon their discovery; however, they are critical mediators in biological robustness by buffering off the small perturbations, thus ensuring homeostasis of organisms. Almost 60% of protein-coding genes are subject to miRNAs regulation in humans [36]. They downregulate gene expression via complementarily binding to the 3′ UTR of target mRNA. The role of miRNAs, either oncomiRNAs or tumour suppressors, depends on the role of their target genes. More than 50% of miRNA genes are located closely within CGIs, thereby they are susceptible to other epigenetic modifications [37]. Nowadays, a growing number of studies have revealed the mechanisms of miRNAs in almost all types of cancers.

LncRNAs represent a diverse family of long transcripts generated from different genomic locations. They can influence the target sites either within the nucleus or cytoplasm and play many characters such as chromatin regulators, enhancers, ncRNAs sponge, molecular scaffold, etc. In general regards, lncRNAs are similar with mRNAs that undergo splicing, 5′-cap, and polyadenylation, except newly discovered circular RNAs (circRNAs) which have no cap and poly-A tail [38]. Recent advances have rectified that lncRNAs and circRNAs enable to encode functional peptides with short open reading frames (sORFs), which make their mechanisms more complicated [39].

Aberrant epigenetic changes in cancer development
Intratumor epigenetic alterations
Tumorigenesis is a consequence of accumulating changes in genome and epigenome, which confers tumours with traits of heterogeneity and plasticity. Two models have been proposed to decipher how tumours progress: (i) the cancer stem cell (CSC) model, also termed the hierarchical model, regards cancer stem cells as the origin of oncogenic transformation; (ii) the stochastic or clonal evolution model suggests that the initial oncogenic change is acquired progressively by non CSCs [40, 41]. There is no doubt that epigenetic alterations are critically involved in both models as they can regulate genetic deregulation and certain mutations.

The activation of oncogenes and/or suppression of tumour suppressor genes (TSGs) are considered to be one of factors contributed to the onset of cancer, and they are always consistent with epigenetic changes. DNA methylation acts as a switch controlling the “open” and “off” status of the gene expression (Fig. 1). Hypermethylation of promoters in CGIs is the most recognised mechanism of epigenetic alterations in cancer cells and has been well implicated in various cancer types. Abundant TSGs are under hypermethylation, such as RASSF10 in kidney cancer [42], SIX3 in glioblastoma [43], CDKN2A and PTEN in melanoma [44, 45], etc. Besides, not only TSGs hypermethylation is commonly seen in many cancers, but additional genes involved in multiple pivotal cellular functions also present hypermethylation. The studies of prostate cancer (PC) have demonstrated that the heavily methylated situation occurred on the promoters of glutathione S-transferase pi (GSTP1) and other genes such as CDKN2A, TIMPS, and DAPK, which participate in cell cycle, cell metastasis, apoptosis and so forth [46]. By contrast, hypomethylation of oncogenes is commonly reported in multiple cancers, including LY6K in glioblastoma [47], SLC34A2 in papillary thyroid carcinoma [48], RBBP6 in colorectal cancer [49], etc. Moreover, instead of targeting specific genes individually, the variation of DNA methylation is likely to be a genome-wide regulatory scheme. Latest study of genomic and epigenomic landscape in hepatocellular carcinoma (HCC) found that hyper- and hypomethylation occurred in the early preneoplastic phases of HCC, which was significantly relevant to deregulation of cancer-related genes [50].

Apart from aberrant DNA methylation, unbalanced histone modification is abused by those cancers that adhere to the CSC model, in which bidirectional interconversions
are essential. The bivalent histone marks, activating H3K4me3 and repressive H3K27me3, are originally addressed in the differentiation of embryonic stem cells (ESCs) [51]. However, some types of cancers partially recapitulate this bivalency to deregulate oncofetal genes in cancer cells [52–54]. In colorectal cancer, some genes that supposed to be stem cell markers underwent H3K27me3 loss, such as SOX9, LGR5, ASCL2, OLFM4, EPHB3 [55]. In addition, the bivalency of histone marks on EMT-related genes (e.g. CDH1, SNAI1, TWIST1) confers them bipotential capacity to potentiate cancer plasticity [56–58].

Aberrant epigenetic alterations on chromosome are dimensionally complex as they are likely to coact during tumorigenesis. Recent studies have demonstrated that histone modifications can be altered along with abnormal DNA methylation or noncoding RNAs. Even one type of histone alteration can affect other histone marks. For example, H3K36me2 expansion caused by NSD2 overexpression in multiple myeloma favored the enrichment of H3K27ac and interactions with other regulatory elements, thus activating oncogenic pathways [59]. Increasing evidence supported that abnormal epigenetic changes may either arise stochastically or be driven by transcriptional program, indicating that the mutations in key elements of epigenetic regulation (e.g. DNMTs, TETs, EZH2, etc.) or specific signalling pathways (e.g. EGFR and KRAS signalling) can modify epigenome [43].

In addition to abnormalities at chromosome level, variations in ncRNAs and RNA modifications are very common in cancer cells. Up to now, tons of aberrant miRNAs are being found in almost every type of cancers. The putative onco-miRNAs (e.g. miR-21, miR-155, miR-210, miR-221, etc.) are usually upregulated in cancer and confer cancer cells advantageous traits by targeting TSGs. By contrast, tumour suppressor miRNAs (e.g. miR-34 family, miR-200 family, etc.) exhibit the opposite function in
and apoptotic vesicles [72]. They contain DNA fragments, mRNAs and noncoding RNAs and serve as pivotal communicating messengers between cells in early stages of premetastatic niche formation and are critically associated with EMT and metastatic progress [73]. For instance, the exosomal miR-200b was higher in pancreatic ductal adenocarcinoma (PDAC) and indicated shorter overall survival (OS) [74]. It was reported that Non-small cell lung cancer (NSCLC) cell-derived exosomes were overexpressed miR-619-5p that induced cancer cells growth and metastasis by suppressing RCAN1.4 [75]. Moreover, the miRNAs translocated to paracancerous cells can deliver oncogenic signals to shape beneficial TME. In the pre-metastatic niche of colon-rectal cancer (CRC) cells, the exosomal miR-25-3p was transferred to endothelial cells to promote vascular permeability and angiogenesis [76]. The BRACA1-KO fibroblasts that exposed to CRC-derived EVs underwent phenotypical transformation, which was likely caused by cancer DNA, mRNA and miRNAs in EVs [77]. MiR-409 and miR-154* are found to be expressed in carcinoma-associated fibroblasts (CAFs) which supposed to be silenced after early embryogenesis [78].

It has been widely known that the whole process of tumorigenesis requires an immune-suppressive environment which enables tumour cells to escape from immune surveillance and T cells-regulated anti-cancer killing. Utilizing the inhibitory immune checkpoint pathway to prevent immune system is one of strategies. The most broadly studied checkpoint proteins are engaged in the surface of both T cells and cancer cells, generally serving as receptor and ligands, including CTLA-4/CD80 or CD86, PD-1/PD-L1 or PD-L2, LAG3/MHC-II, TIM3/galectin-9, BTLA/HVEM, TIGIT/CD155 [79, 80]. Induction of those checkpoint proteins can turn T-cells into “off” status, and it is under epigenetic control in cancers. Lower repressive histone marks and DNA methylation marks are usually found at the promoters of checkpoint proteins. It has been reported that PD-1, CTLA-4, TIM-3 and TIGIT were hypomethylated in tumour tissues, compared to the normal tissues, and they also exhibited reduced H3K9me3 and H3K27me3 at their promoters [81, 82]. In addition, ncRNAs are explicitly contribute to epigenetic control in the immune checkpoint that have been summarized in the reference [83]. Except for the role of immune checkpoints in immune suppression, one of the known barriers for deficiency of tumour-infiltrated lymphocytes is the lack of chemokines, including CCL2, CCL4, CXCL8, CXCL9, CXCL10, CXCL12 and CXCL14 etc. These chemokines are supposed to recruit corresponding immune cells into the TME. However, they are epigenetically suppressed in many cancers. For instance, EZH2 was overexpressed to repress the production of T helper 1 (Th1)-type chemokines CXCL9 and CXCL10 via trimethylation at H3K27,
thus establishing an immune suppressive TME for ovarian cancer [84]. In osteosarcomas, CXCL12 was epigenetically reduced by DNMT1 and lead to impair cytotoxic T-cell homing to the cancer cells [85].

**Epigenetics therapy in cancer**

Epigenetic alterations have fundamental functions in cancer progression characterized by reversibility and susceptibility to external factors. They are emerging as promising targets for cancer therapies. The drugs that target the epigenome, called epi-drugs, have been developed more than 40 years. Until now, they have been tested in clinical trials for cancer treatments and displayed favourable outcomes to some extent. A summary of epi-drugs currently in clinical trials can be found in Table 1.

**DNMT inhibitors (DNMTIs)**

DNMTIs are potent anticancer therapeutics to reverse the DNA hypermethylation status of TSGs. According to the regulatory mechanisms to the nucleotides, DNMTIs can be divided into two classes: cytosine analogue inhibitors and non-nucleotide analogue inhibitors. In general regards, cytosine analogues can incorporate into the DNA or RNA backbone to replace C-5 of cytosine with N-5 and disturb the methylation, as well as induce DNMTs degradation. They include 5-aza-cytidine (azacytidine), 5-aza-2′-deoxycytidine (decitabine), zebularine, SGI-110, fazarabine, pseudois cytidine, etc.

Azacytidine and decitabine are cytosine analogue inhibitors and have been approved by the FDA for the treatment of hematologic malignancies, specifically myelodysplastic syndrome (MDS) and acute myeloid leukaemia [86, 87]. Nowadays, they are widely implicated in different solid tumours. Azacytidine has a large portion incorporated into RNA, while decitabine is only incorporated into DNA. The action of decitabine starts with DNA integration. After that, the formed azacytosine-guanine dinucleotides trap DNMTs with irreversible covalent bindings, thereby exhausting DNMTs and removing the DNA methylation marks on the promoters of TSGs [88]. Furthermore, DNA damage response is triggered along with this process and leads to cell cycle arrest, growth suppression, and apoptosis. As for azacytidine, given to its capacity in the incorporation of RNA, recent studies demonstrated that it can block gene translation via disrupting tRNA-rRNA interactions and inhibit the conversion of deoxyribonucleotides [89]. The anti-tumour activities of these two drugs have been determined in clinical trials at relatively low doses due to their high toxicity caused by high doses.

Apart from azacytidine and decitabine, there are many other cytosine analogues that function in different mechanisms, such as zebularine (ZEB), 6-thioguanine, and 4′-thio-2′-deoxycytidine. ZEB contains a 2-(1H)-pyrimidinone ring that leads to degradation of DNMTs via forming a covalent complex with DNMTs at position 6 of the pyrimidinone ring after DNA incorporation [90]. Distinct from azacytidine and decitabine, which can be deactivated by cytidine deaminase (CD), ZEB is more stable with a long half-life that enables oral administration [91]. Of note, ZEB has a preferential response to tumour cells because of faster DNA incorporation and higher response [92, 93]. Although ZEB alone is not as efficient as azacytidine or decitabine due to the competitive effect of cytidine deaminase, it facilitates preventing re-methylation of the gene after treatment of other DNMTIs and may lower doses of DNMTIs [94]. For example, p16 expression may occur re-silence by DNA methylation after decitabine treatment in bladder cancer cells. However, with the addition of ZEB administration, the demethylation effect could be maintained [84]. Therefore, it also combines with azacytidine and decitabine and displays much safer in various cancer treatments, such as AML and EBV-positive Burkitt’s lymphoma [95].

In a class of non-nucleotide analogue inhibitors, they are small molecules that prevent the binding of DNMTs to the target sequences either by binding to the catalytic site of DNMTs or binding to the CpG-rich sequences. They include hydralazine, EGCG, RG108, MG98, and disulfiram, etc. Those epi-drugs have slightly inhibitory effects to multiple cancer cells compared with those cytosine analogue inhibitors. MG98 is an antisense oligonucleotide that targets 3′UTR of DNMT1 and induces demethylation in vitro and in vivo [96]. The significant inhibition of DNMT1 expression was observed in phase I clinical study. However, no detectable effect was noted in phase II clinical trial in patients who suffered metastatic renal carcinoma.

**HDAC inhibitors (HDACIs)**

HDACIs are capable of rectifying the aberrant acetylation status of histones and non-histone proteins in cancers via reactivation of TSGs. Also, cancer cells exhibit a higher sensitivity in response to HDACIs-induced apoptosis. Those features make them become a promising target in cancer therapy. Based on their structure, HDACIs can be divided into four groups: hydroxamic acids, cyclic peptides, aliphatic fatty acids, and benzamides.

The hydroxamic acid HDACIs contain a hydroxamic acid moiety that can bind to the zinc atom, a component in the catalytic sites of HDACs, thus inactivating HDACs. Multiple studies have demonstrated their success in treating both hematologic malignancies and other solid tumours. Currently, three general hydroxamic acid HDACIs have been approved by FDA: (i) Vorinostat (SAHA) which is responsible for cutaneous T-cell
**Table 1** Epi-drugs currently in clinical trial

| Target | Drug | Therapeutic Strategy | Cancer/Disease | Phase | Reference/ NCT no. |
|--------|------|----------------------|----------------|------|-------------------|
| DNMT  | Azacytidine (Vidaza*) | Monotherapy | MDS, AML | FDA approved | [86] |
|       | Polytherapy (cytarabine) | AML | | III | [158] |
|       | Decitabine (Dacogen*) | Monotherapy | MDS, AML | FDA approved | [87] |
|       | Polytherapy (Talacotuzumab) | AML | | III | [159] |
|       | Disulfiram | Polytherapy (Chelated Zinc) | Melanoma | II | NCT02101008 |
|       | ECGG | Polytherapy (Green tea) | PC | II | NCT00666562 |
|       | hydralazine | Polytherapy (magnesium valproate) | Refractory solid tumour | II | [160] |
|       | SGI-110 | Monotherapy | HCC | II | NCT01752933 |
|       | Polytherapy (Pemetrexed, Cisplatin, Gefitinib) | NSCLC | | II | [161] |
|       | 6-thioguanine | Polytherapy (Dexamethasone, Cyclophosphamide, Vincristine etc.) | Lymphoma | IV | [162] |
|       | 4′-thio-2′-deoxycytidine (TdCyd) | Monotherapy | Solid tumour | I (recruiting) | [163] |
|       | MG98 | Monotherapy | Solid tumour | I | [164] |
| HDAC  | Abexinostat (PCI-24781) | Monotherapy | Lymphoma | I & II | [165] |
|       | Polytherapy (Doxorubicin) | Sarcoma, lymphoma | I & II | [166] |
|       | CUDC-101 | Monotherapy | Solid tumour | I | [167] |
|       | Belinostat (Beleodaq/PXD101) | Monotherapy | PTCL; HCC, Burkitt lymphoma, DLBCL, thymic carcinoma, MDS | FDA approved; | [98] |
|       | Polytherapy (Paclitaxel, Carboplatin) | Ovarian cancer, fallopian tube cancer, bladder cancer | I & II | NCT00421889 |
|       | Entinostat (SNDX-275) | Polytherapy (Entinostat, Exemestane, Placebo) | Breast cancer | I | [169] |
|       | Givinostat (ITF2357) | Monotherapy | Polycythemia vera | I & II | NCT01901432 |
| HDAC  | Mocetinostat (MGCD0103) | Polytherapy (Gemcitabine) | Metastatic leiomyosarcoma | II | NCT02383262 |
|       | Panobinostat (LBH-589) | Monotherapy | MM; thyroid carcinoma, RCC, breast cancer, AML | FDA approved; | [99] |
|       | Polytherapy (Placebo) | Hodgkin’s lymphoma, MM | III | [170] |
|       | Pracinostat (SB939) | Monotherapy | MLD | III | [171] |
|       | Polytherapy (Ruxolitinib) | MLD | II | NCT02267278 |
|       | Romidepsin (Depsipeptide/FK228) | Monotherapy | CTCL, PTCL | FDA approved | [101] |
|       | Polytherapy (Alisertib, Palatrexate, Gemcitabine) | Relapsed PTCL | III | NCT01482962 |
|       | Valproic acid (VPA) | Polytherapy (Azacytidine, All-trans retinoic acid) | MDS, AML | II | [172] |
|       | Vorinostat (SAHA) | Monotherapy | CTCL | | [173] |
|       | Polytherapy (KW-0761) | AML | | | [174] |
|       | BET I-BET762 (GSK525762/molibresib) | Monotherapy | Neoplasms | II | NCT01943851 (recruiting) |
|       | Polytherapy (Abiraterone, Enzalutamide, Prednisone) | Solid tumour | I | NCT03150056 (recruiting) |
lymphoma (CTCL) [97]; (ii) Belinostat (PXD101) which is responsible for peripheral T-cell lymphomas (PTCL) [98]; and (iii) Panobinostat (LBH-589) which is responsible for multiple myeloma [99]. SAHA is a non-selective broad-spectrum HDACIs that inducing acetylation of histones. It has been reported to enhance the expression of p21 by inducing acetylated histone H3 and H4 in bladder carcinoma and endometrial stromal sarcomas [100]. Also, there are other hydroxamic acid HDACIs similarly displaying inhibitory effects on HDACs either selectively or generally, including resminostat, givinostat, pracinostat, abexinostat, and quisinostat, etc. They have been implicated in phase I or II clinical trials for multiple cancers.

Romidepsin (FK2280) is a member of cyclic peptide HDACIs and has received approval of the FDA in 2009 and 2011 for the treatment of CTCL and PTCL respectively [101]. It undergoes reduction by glutathione and releases a zinc-binding thiol within cells. With this thiol, FK2280 interacts more explicitly with class I/II HDACs, leading to reactive target genes [102, 103]. Valproic acid (VPA) is an example of aliphatic fatty acid HDACIs and selectively targets class I/II HDACs. It was originally developed for the treatment of epilepsy, and its application was then extended to anti-tumour treatment due to its ability in suppressing the proliferation and stimulating the differentiation of cancer cells. VPA can increase histone H3 and H4 acetylation and cause demethylation of target genes, especially in nondividing cells. Some of the genes activated by VPA are associated with cancer metastasis (e.g., MMPs) or tumour-specific antigens (e.g., MAGEB2) [104]. Moreover, VPA has a property of low toxicity, well tolerance, and stability, which makes it a promising epi-drug. Phenylbutyrate, AR-42, and pivanex (AN-9) are other members of short-chain fatty acid HDACIs.

Benzamide derivative was firstly reported by Suzuki et al. in the 1990s and displaying significant HDACs

### Table 1 Epi-drugs currently in clinical trial (Continued)

| Target Drug | Therapeutic Strategy | Cancer/Disease | Phase | Reference/ NCT no. |
|-------------|----------------------|----------------|-------|---------------------|
| OTX-015 (MK-8628) | Monotherapy | AML, DLBL, ALL, MM | I | [175] |
| TEN-010 (RO6870810) | Monotherapy | Advanced solid tumors | I (recruiting) | NCT01987362 |
| CPI-0910 | Polytherapy (atezolizumab, daratumumab, venetoclax, rituximab) | Advanced MM | I (recruiting) | NCT03292172 |
| FT-1101 | Polytherapy (Azacitidine) | AML, non-Hodgkin lymphoma | I | NCT02543879 |
| BET ZEN003694 | Polytherapy (Talazoparib) | TNBC | II | NCT03901469 |
| BMS-986158 | Monotherapy | Lymphoma, brain tumour | I (recruiting) | NCT03936465 |
| PRIN0012 (mir-34) | Monotherapy | Primary liver cancer, SCLC, lymphoma, MM, RCC | I | NCT01829971 |
| MRG110 (anti-miR-92) | Polytherapy (Placebo) | Wound healing | I | NCT03603431 |
| MRG201 (miR-29) | Polytherapy (Placebo) | Fibrous scar tissue formation | I | NCT02602224 |
| MRG106 (miR-155) | Polytherapy (Cobomarsen, SAHA) | CTCL, Mycosis fungoides | II | NCT03713320 |
| Patisiran | Monotherapy | Rare polyneuropathy | FDA approved | [136] |
| RG-012 (anti-miR-21) | Monotherapy | Alport syndrome | I | NCT03373786 |
| TargomiRs (miR-15/17) | Monotherapy | Malignant pleural mesothelioma, NSCLC | I | [176] |
inhibition [105]. Entinostat (MS-275) and tacedine (CI-994) are very active HDACIs of the benzamide group. They possess a 2′-aminophenyl group that binds to the specific site of class I HDACs and display inhibitory effect on HDACs. The treatment of MS-275 could induce expression of multiple genes and increased the overall acetylation status of histones in vitro and in vivo [106]. It was also well-tolerated for patients with lymphoid malignancies and solid tumours in phase I and II clinical trials. Similarly, CI-994 has been tested in phase II clinical trials and could be used alone or in combination with other chemotherapeutic drugs to treat solid tumours in patients [107, 108].

Bromodomain and extra terminal inhibitors (BETIs)
The BET is a family of proteins that contain two N-terminal tandem bromodomains and a C-terminal extra terminal motif, including BRD2, BRD3, BRD4, and BRDT. They form a complex in association with HDACs and other proteins to stimulate transcriptional activity. BRD4 is the most characterized BETs which is exceptionally involved in transcriptional regulation and cancer progression due to its capacity of assembling on both hyper-acetylated gene promoters and “super-enhancers” to promote RNA-pollII-mediated transcriptional initiation and elongation [109, 110]. Several oncogenes have been described as the effectors of BRD4, including c-Myc, FOSL1, RUNX2, BCL-2, and c-KIT [111–114]. The efficacy of BETIs is based on the disruption of BETs-acetylated histones interaction. So far, several BETIs have encouraging clinical outcomes with tolerable toxicity and potent efficacy, including thienodiazepine JQ1, I-BET762 (GSK525762), I-BET151 (GSK1210151A), GSK-5829, CPI-0610, TEN-010, OTX-015, and ZEN003694.

JQ1 has been reported to block the interactions of BRD2/3/4 and acetylated histones selectively. One of the target genes c-Myc is subject to downregulation by JQ1 in many different cancers [115]. Furthermore, it exhibits a drastically anti-tumour activity even in castration-resistant cells by disrupting BRD4-mediated androgen receptor (AR) recruitment and transactivation. Recent studies have reported that JQ1 also increased cytotoxic T-cell response by increasing PD-L1 expression [116]. A new oral derivative of JQ1, OTX015, has been synthesized to function as an inhibitor of BRD2/3/4 [117]. Administration of OTX015 could diminish the phenotype of CSCs, providing a compelling strategy in the most aggressive PC [118].

Histone methyltransferases/demethylases inhibitors
EZH2 is a histone methyltransferase and is responsible for the catalytic activity of PRC2. EZH2/PRC2 methylates H3K27 and leads to transcriptional silence of target genes in multiple subtypes of cancers, including ovarian cancer, breast cancer, PC, T-cell ALL and non-Hodgkin lymphoma [119–128]. Small molecule EZH2 inhibitors, such as EPZ-6438 (tazemetostat), GSK2816126, and CPI-1205, have been evaluated in clinical trials and showed antineoplastic effects in both hematologic malignancies and various solid tumours. EPZ-6438 is an orally bioavailable EZH2 inhibitor by competing with SAM, which is a cofactor of EZH2 [128]. With encouraging phase I and II clinical trials, EPZ-6438 has been granted as a Fast Track designation for diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL), as well as Orphan Drug designation for malignant rhabdoid tumours by FDA [129].

Another group of epigenetic drug precursor is histone demethylase inhibitor, including inhibitors of LSD1 and Jumonji (JmJc). The effect of LSD1 inhibitors is based on the impairment of the H3K4 demethylation [130]. LSD1 inhibitors have been grouped into four classes: (i) reversible poly- or monopeptide inhibitors, (ii) irreversible derivatives of monoamine oxidase inhibitors, (iii) rationally designed fusions of active molecules, and (iv) novel compounds not known to inhibit monoamine oxidase (MAOI). For example, the highly selective LSD1 inhibitors, such as namoline, HCI-2509, NCL-1, have been identified to be reversible inhibitors that have the robust capability of impairing H3K4 demethylation. The treatment of these LSD1 inhibitors can lead to androgen-independent growth arrest without apparent adverse effects in castration-resistant PC cells both in vitro and in vivo [131–133]. The inhibitors of JmJc, which include hydroxamate derivatives, pyridine dicarboxylates, N-oxalyl amino acid derivatives, and agents that interfere with metal binding, have been designed by targeting the 2-OG of the JmJc family, which is a key component for demethylation of methylated lysine [134, 135].

NcRNAs
Increasing studies have shown that miRNAs become biomarkers of multiple cancers as their abnormal levels may be considered to indicate the stage of pathology and prognosis. The applications of miRNAs analogue or anti-miRNAs have shown compelling outcomes in-vitro and in-vivo cancer studies, suggesting the miRNA-based drugs are emerging as a novel strategy for cancer therapy. Nowadays, the first small-interfering RNA (siRNA), patisiran, has got approval from the FDA in 2018 for the treatment of rare polyneuropathy via targeting and degrading the mRNA transcription of transthyretin [136]. Many other miRNA-based drugs are under clinical trials and may be translated into FDA-approved drugs in the future, including liposome-formulated miR-34a mimic (MRX34), MRG110, MRG-201, MRG-106, RG-012, RGLS5579, and TarpgomiRs (miR-15/17 consensus sequences). They either function as miRNA mimics or miRNA antagonists in the
treatments of different cancers. For example, the expression of tumour suppressor miRNA-34a is usually relatively low in various cancers, such as PC, NSCLC, and ALL, and it has been identified as a tumour suppressor with multiple targets, including CD44, PD-L1, ZEB1, and BCL-2. MRX34 has been developed as a novel strategy to increase the miR-34a level for cancer therapy and has been launched a phase II clinical trial [137]. In terms of higher expression of onco-miRNAs in specific malignancies, the antagoniR-mediated inhibition of specific miRNAs is highly recommended in clinical trials. A latest study has shown that antagoniR-214 decreased disease severity in CTCL, which provides another angle of view for CTCL therapy [138]. Although JQ1 could also downregulate miR-214, indicating the upregulation of miR-214 was caused by aberrant histone acetylation [138].

Numerous lncRNAs are subsequently identified and found to be aberrantly expressed in various tumours. Due to the multifaceted regulations and intricate mechanisms of lncRNAs, few of them have been already implicated as drugs for clinical therapies. However, they are capable of functioning as indicative of the severity of specific cancers as they are supposedly stable in body fluid. For example, the higher lncRNA PCA3 in urine may correspond to the severity of prostate cancer [139]. LncRNA MALAT1, NEAT1, UCA1, and ANRIL can seem as biomarkers for metastatic lung cancers [140]. Similar to the miRNA-mediated strategies, antisense-mediated lncRNA targeting is also shown to be a promising tool for some cancer therapies [141]. So far, there are still many hurdles regarding the clinical application of ncRNAs; introducing those ncRNAs with efficient delivery systems is always a potential strategy in cancer therapy.

Epi-drugs combined therapy

The administration of multiple epi-drugs themselves or in combination with chemotherapy and immunotherapy is becoming a novel approach due to its augmentation of anti-tumoral effects and overcoming drug resistance. The impact of multiple epi-drugs treatments is based on the synergistic actions of epi-drugs. For example, SAHA and panobinostat co-treatment displayed robust anti-cancer activity in colon adenocarcinoma and leukaemia via inducing immunogenic cell death (ICD) [142]. The treatment of SAHA with panobinostat is reported to epigenetically silence the AR gene and repress transcription of the AR targeted genes PSA and tMPRSS2 [143]. The combination of JQ1 or EZH2 inhibitors with panobinostat presents synergistic effects in vitro and in vivo [144, 145].

So far, chemotherapy is still a traditional method for advanced cancers that lack the opportunity for surgical excision. The emergence of chemoresistance becomes a great hindrance to cancer therapy. One of the reasons is that some chemotherapy agents can bring into aberrant epigenetic changes after treatment. For example, cisplatin treatment in ovarian cancer can induce hypermethylation of multiple genes (e.g., MLH1, MEST, MDK) and lead to the acquired resistance phenotype [146]. The addition of decitabine can abate and even reverse the resistance to cisplatin via re-activating those epigenetically silenced genes, suggesting that combining epi-drugs with other chemotherapeutic agents can not only remarkably promote potent suppression of tumorigenesis, but also re-sensitize tumour cells to radiotherapy and chemotherapy. The studies of HCC have found HDAC3 and HDAC5 mRNAs were upregulated. Inhibiting those HDACs with LBH-589 could increase acetylation of histone H3 and HSP90 and upregulate CDH1 [147]. The SHELTER studies also investigated that the combination of sorafenib (an FDA approved systemic drug) and resminostat, which is an oral pan-HDACi with predominant activity against HDAC1, 2, and 3, showed a compelling outcome with a 2-fold increase of overall survival (OS) in a second-line setting of advanced HCC, compared to monotherapy of resminostat [148].

Immune checkpoint inhibitors (ICIs) have been considered as a great breakthrough for the treatment of malignant diseases. PD-1/PD-L1 and CTLA-4 inhibitors are the most promising ICIs that some of them have been approved for certain malignancies therapies. However, the clinical benefit of ICIs is obstructed by the lack of surface markers for antigen presentation, impaired T cell response, re-educated TME, etc. To some extent, those hinder can be overcome by epigenetic reprogramming. Recent studies have provided evidence that the efficacy of PD-1 antibodies can be potentiated by using the DNMTIs. In breast cancer, the major histocompatibility class-I (MHC-I)-encoding genes were methylated and sustained in silence expression status. The treatment with guadecitabine, one of DNMTIs, could enhance MHC-I expression and increase CD8+ T cell infiltration in TME [149]. Those reactions could further potentiate subsequent responses to PD-1 antibodies. Another example is the effect of decitabine in sensitizing CD8+ T cells to PD-L1 antibodies via disrupting the DNMT3A-mediated methylation in exhausted T cells [150]. The administration of belinostat was reported to induce CTLA-4 inhibition, which was responsible for M1-phenotypic tumour-associated macrophages (TAMs), and decrease splenic regulatory T cells (Tregs) [151]. Many other epi-drugs (e.g. JQ1, LSD1 inhibitors, and EZH2 inhibitor) in combination with anti-PD1 therapy, have been revealed that they can increase anti-tumour immune response via enhancing T-cell persistence in different cancers, such as lung cancer, TNBC, and lymphoma, etc. [116, 152]
Discussion
Notwithstanding, compelling evidence has described that implying epi-drugs alone or in combination with other drugs in clinical trials, can improve the anti-tumour efficacy. However the accompanying problems may not be underestimated. Firstly, a considerable number of epigenetic compounds are still ongoing in laboratory investigation. The major challenge for those compounds would be how to translate the efficacy in vitro with nanomolar-scale concentrations into well-tolerated and efficient clinical use. MG98 has been found to efficiently reactivate silenced TSGs via downregulation of DNMT1 in several cancer cell lines at concentrations of 25–76 nM and presented inhibitory effect on proliferation. However, it did not achieve significant response in clinical trials [153]. The off-target of epi-drugs is another problematic issue. As epigenetic regulation is multifaceted, dynamic, and interdependent, the mechanism behind is not clear. Currently, some commonly used epi-drugs, such as VPA, have been known to generate unwanted epigenetic modifications [154, 155]. A well-established safety profile of those epi-drugs are needed to make ease for their applicability in clinical therapy. Meanwhile, the acquired resistance to some of the epi-drugs is becoming a hurdle. The BETIs resistant AML cells displayed PRC2 suppression, which may recover the BETI-targeted c-Myc expression [156]. The hyperphosphorylation of BRD4 is also promoting BETI resistance in triple-negative breast cancer (TNBC) [157].

Conclusion and future perspectives
Epigenetics represents a series of dynamic alterations which is independent of genetic changes. They are critically involved in the onset and development of tumorigenesis by regulating the on and off states of oncogenes and TSGs, as well as TME reengineering. Remarkably, epigenetic modifications feature properties of heritable and reversible regulations, making them a promising target for cancer therapy. Current epi-drugs have been used in different cancer types either in a single treatment or a combined treatment with other anti-cancer agents, showing compelling outcomes in some extent. However, the subsequent shortcomings are needed to be considered.

Since human cancer features properties of heterogeneity and plasticity, the request for a precise and effective personalized therapy using epi-drugs is being brought into concern. The standard anti-cancer therapy for general cancer patients has received very limited prognosis due to individual differences. With the advent of high throughput epigenome mapping technologies, the genome and epigenome map of a specific cell population from the patient are available for drug sensitivity testing and drug screening. In this way, the treatments can be optimized for each patient while having much efficiency and less off-target effects.

Abbreviations
S-5-caC: S-carboxylycysteine; S-5-FC: S-formylycysteine; S-5-hmC: S-5-hydroxymethylcytosine; m5SC: S-methylcytosine; AR: Androgen receptor; BETIs: Bromodomain and Extra Terminal inhibitors; CAFs: Carcinoma-associated fibroblasts; CGIs: CpG islands; CDKN2A: Cyclin-dependent kinase inhibitor 2A; CD: Cytidine deaminase; CTLA-4: Cytotoxic T-lymphocyte associated protein 4; DAPK: Death-associated protein kinase; DLBCL: Diffuse large B cell lymphoma; DNMTs: DNA methyltransferases; DNMTIs: DNMT inhibitors; EZH2: Enhancer of zeste 2; EMT: Epithelial-mesenchymal transition; eIF3: Eukaryotic initiation factor 3; GSTP1: Glutathione S-transferase pi; H3K27me3: H3K27 trimethylation; HDACIs: HDAC inhibitors; HCC: Hepatocellular carcinoma; HNRNP: Heterogenous nuclear ribonucleoprotein; H2A: Histone 2A; H2B: Histone 2B; H3: Histone 3; H4: Histone 4; HATs: Histone acetyltransferases; HDACs: Histone deacetylases; HDMTs: Histone demethylases; HMTs: Histone methyltransferases; HIF-1a: Hypoxia-induced factors 1a; ICIs: Immune checkpoint inhibitors; IC: Immunogenec cell death; IGF2BP: Insulin-like growth factor 2 mRNA binding proteins; IncRNAs: Long non-cRNAs; LAG-3: with galectin-9; Lymphocyte activating 3, H3K4/79: Lysine 4/79 of histone H3; MHC-I: Major histocompatibility class-I; MBDS: Methyl-binding domain proteins; METTL3: Methyltransferase-like 3; MDS: Myelodysplastic syndrome; m5APA: N5-methyladenosine methylation; ncRNAs: Non-coding RNAs; OS: Overall survival; PTCL: Peripheral T-cell lymphomas; PTM: Post-translational modifications; PD-1: Programmed death-ligand 1; PC: Prostate cancer; Tregs: Regulatory T cells; RBM15/15B: RNA binding motif protein; SAM: S-adenosylmethionine; snRNAs: Small ncRNAs; siRNA: Small interfering RNA; Th1: T helper 1; TIM-3: T-cell immunoglobulin mucin 3; TET1: T-cell lymphoma; TIMPs: Tissue inhibitors of metalloproteinases; TFs: Transcriptional factors; TNBC: Triple-negative breast cancer; TME: Tumour microenvironment; TSGs: Tumour suppressors genes; TAMS: Tumour-associated macrophages; VPA: Valproic acid; WTAP: Wilms tumour 1-associated protein; YTH: YTH domain-containing 1; ZEB: Zebrin; ZC3H13: Zinc finger CCCH-type containing 13

Acknowledgements
Authors would like to thank Mr. Keith Wong, Mr. Alex Shek and Ms. Cindy Lee for their assistance.

Authors' contributions
Y.F. and N.W. conceived the idea, design the study, drafted the manuscript; Y.F. and N.W. conceived the idea, design the study, drafted the manuscript; F.C. and T.C. contributed to the data collection and analysis; H.Y.T and S.L. polished the manuscript. The authors read and approved the final manuscript.

Funding
This research was partially supported by the Research Council of the University of Hong Kong (project codes: 104004092 and 104004460), Wong’s donation (project code: 200006276), a donation from the C. Family Trust of New Zealand (project code: 200007008), the Cancer Council Committee (RGG) of Hong Kong, HK Scholar (Project codes: 740608, 766211, 17152116 and 17121419), Health and Medical Research Fund (Project code: 15162961, 16172751), Enhanced new staff start-up fund (Project code: 204610519) and Preemptive retention fund (Project code: 202007002).

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.
References

1. Waddington C. The evolution of an evolutionist. Edinburgh: Edinburgh Univ. Press; 1975.
2. Bird A. Perceptions of epigenetics. Nature. 2007;447:396.
3. Liang G, Chan MF, Tomigahara Y, Tsai Y-C, Gonzales FA, Li E, Laird PW, Jones PA. Cooperative between DNA methyltransferases in the maintenance DNA methylation of repetitive elements. Mol Cell Biol. 2002;22:480-91.
4. Easwaran H, Tsai H-C, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54:716-27.
5. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to DNA demethylation in cancer. Genome Med. 2015;7:1090-79.
6. Pradhan S, Talbot D, Sha M, Benner J, Hornstra L, Li E, Jaenisch R, Roberts RJ. Baculovirus-mediated expression and characterization of the full-length recombinant human DNA methyltransferase. Nucleic Acids Res. 1997;25:4666-73.
7. Goyal R, Reinhardt R, Jetten A. Accuracy of DNA methylation pattern preservation by the Dnmt1 methyltransferase. Nucleic Acids Res. 2006;34:1182-8.
8. Liang G, Chan MF, Tomigahara Y, Tsai Y-C, Gonzalez FA, Li E, Laird PW, Jones PA. Cooperation between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol. 2002;22:480-91.
9. Schumann U, Shafik A, Preiss T. METTL3 gains R/W access to the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24:177.
10. Jin B, Tao Q, Peng J, Siao HM, Wu W, Ying J, Fields CR, Delmas AL, Liu X, Qiu J. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. Hum Mol Genet. 2007;16:690-709.
11. Pradhan S, Talbot D, Sha M, Benner J, Hornstra L, Li E, Jaenisch R, Roberts RJ. Baculovirus-mediated expression and characterization of the full-length recombinant human DNA methyltransferase. Nucleic Acids Res. 1997;25:4666-73.
12. Goyal R, Reinhardt R, Jetten A. Accuracy of DNA methylation pattern preservation by the Dnmt1 methyltransferase. Nucleic Acids Res. 2006;34:1182-8.
13. Liang G, Chan MF, Tomigahara Y, Tsai Y-C, Gonzalez FA, Li E, Laird PW, Jones PA. Cooperation between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol. 2002;22:480-91.
14. Schumann U, Shafik A, Preiss T. METTL3 gains R/W access to the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24:177.
15. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to DNA demethylation in cancer. Genome Med. 2015;7:1-16.
16. Zhao H, Chen T. Tet family of 5-methylcytosine dioxygenases in mammalian demethylation. Genes Dev. 2008;647:30-49.
17. Pradhan S, Talbot D, Sha M, Benner J, Hornstra L, Li E, Jaenisch R, Roberts RJ. Baculovirus-mediated expression and characterization of the full-length recombinant human DNA methyltransferase. Nucleic Acids Res. 1997;25:4666-73.
18. Goyal R, Reinhardt R, Jetten A. Accuracy of DNA methylation pattern preservation by the Dnmt1 methyltransferase. Nucleic Acids Res. 2006;34:1182-8.
19. Liang G, Chan MF, Tomigahara Y, Tsai Y-C, Gonzalez FA, Li E, Laird PW, Jones PA. Cooperation between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol. 2002;22:480-91.
20. Schumann U, Shafik A, Preiss T. METTL3 gains R/W access to the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24:177.
21. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to DNA demethylation in cancer. Genome Med. 2015;7:1-16.
22. Zhao H, Chen T. Tet family of 5-methylcytosine dioxygenases in mammalian demethylation. Genes Dev. 2008;647:30-49.
23. Pradhan S, Talbot D, Sha M, Benner J, Hornstra L, Li E, Jaenisch R, Roberts RJ. Baculovirus-mediated expression and characterization of the full-length recombinant human DNA methyltransferase. Nucleic Acids Res. 1997;25:4666-73.
24. Goyal R, Reinhardt R, Jetten A. Accuracy of DNA methylation pattern preservation by the Dnmt1 methyltransferase. Nucleic Acids Res. 2006;34:1182-8.
25. Liang G, Chan MF, Tomigahara Y, Tsai Y-C, Gonzalez FA, Li E, Laird PW, Jones PA. Cooperation between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol. 2002;22:480-91.
26. Schumann U, Shafik A, Preiss T. METTL3 gains R/W access to the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24:177.
27. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to DNA demethylation in cancer. Genome Med. 2015;7:1-16.
51. Blanco E, González-Ramírez M, Alcaine-Colet A, Aranda S, Di Croce L. The bivalent genome: characterization, structure, and regulation. Trends Genet. 2019;36:118–31.

52. Dhar SS, Lee S-H, Chen K, Zhu G, Oh W, Alton K, Gafni O, Kim YZ, Tomaiga AS, Bantor MC. An essential role for UTxa in resolution and activation of bivalent promoters. Nucleic Acids Res. 2016;44:3659–74.

53. Zaid SK, Frieze SE, Gordon JA, Heath JL, Missier T, Hong D, Boyd JR, Kang M, Imbalzano AN, Lian JB. Bivalent epigenetic control of oncogene gene expression in cancer. Mol Cell Biol. 2017;37:e00352–17.

54. Missier TL, Boyd JR, Gordon JA, Stein JL, Lian JB, Stein GS. Oncofetal epigenetic bivalency in breast cancer cells: H3K4 and H3K27 tri-methylation as a biomarker for phenotypic plasticity. J Cell Physiol. 2016;231:2474–81.

55. Hahn MA, Li AX, Wu X, Yang R, Drew DA, Rosenberg DW, Pfeffer GP. Loss of the polycomb mark from bivalent promoters leads to activation of cancer-promoting genes in colon tumors. Cancer Res. 2014;74:3617–29.

56. Cui H, Hu Y, Guo D, Zhang A, Gu Y, Zhang S, Zhao C, Gong P, Shen X, Li Y. DNA methyltransferase 3A isoform b contributes to repressing E-cadherin through cooperation of DNA methylation and H3K27/H3K9 methylation in EMT-related metastasis of gastric cancer. Oncogene. 2018;37:4358–71.

57. Sui A, Xu Y, Yang J, Pan B, Wu J, Guo T, Shen Y, Guo X. The histone H3 Lys 27 demethylase KDM6B promotes migration and invasion of glioma cells partly by regulating the expression of SNAI1. Neurochem Int. 2019;124:123–9.

58. Malouf GG, Taube JH, Lu Y, Roy sarkar T, Pan sarian S, Esteo MR, Jel nke J, yamazaki J, Raynauld NJ, Long H. Architecture of epigenetic reprogramming following Tng-mediated epithelial-mesenchymal transition. Genome Biol. 2013;14:R44.

59. Lhoumaud P, Badri S, Rodriguez-Hernaez J, Sakellaropoulos T, Sethia G, Klot gen A, Cornwell M, Bhattacharya S, Ay F, Bonneau R. Nsd2 overexpression drives clustered chromatin and transcriptional changes in a subset of induced disorders. Nat Commun. 2019;10:1–18.

60. Rezaei T, Mansoori B, Hashemi ZS, Amini M, Rezaei S, Karami H, Mosafer J, Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, Stampfer MR, Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, Esteller M. DNA methyltransferases as epigenetic markers for prostate cancer. Front Genet. 2014;5:12.

61. White TE, Hovens L, Bresse E, Bilezikian J, Schlange T, Rinn JL. A regulatory role for H3K27 methylation during the transition to cancer. Genes Dev. 2013;27:2195–206.

62. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Blanco E, González-Ramírez M, Alcaine-Colet A, Aranda S, Di Croce L. The miR-200 family and miR-205 regulate the epithelial phenotype of cancer cells by targeting the E-cadherin repressors SNAI1 and SNAI2. Cell Death Differ. 2008;15:1346–57.

63. Neagoe I. A comprehensive picture of extracellular vesicles and their contents. Molecular Transfer to Cancer Cells. Cancers. 2020;12:298.
95. Takemura Y, Satoh M, Hatanaka K, Kubota S. Zebularine exerts its antiproliferative activity through S phase delay and cell death in human malignant mesothelioma cells. Biosci Biotechnol Biochem. 2018;82:1159–64.

96. Yang X, Lay F, Han J, Jones PA. Targeting DNA methyltransferase for epigenetic therapy. Trends Pharmacol Sci. 2010;31:536–46.

97. Mann BS, Johnson JR, Cohen-MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:247–52.

98. McDermott J, Jimeno A. Belinostat for the treatment of peripheral T-cell lymphomas. Drugs Today (Barcelona, Spain: 1998). 2018;54:337–45.

99. Richardson PG, Laubach JP, Lonial S, Moreau P, Yoon S-S, Hungria VT, Dimopoulos MA, Bekac S, Alizina M, San-Miguel JF. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther. 2015;15:377–84.

100. Hzenjak A, Moinfar F, Kermser M-L, Strohmeier B, Petru E, Zatloukal K, Denk H. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010;9:49.

101. Frye R, Myers M, Axelrod KC, Ness EA, Piekarz RL, Bates SE, Booher S. Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. Clin J Oncol Nurs. 2012;16:195–204.

102. Xiao JJ, Byrd J, Marcucci G, Grever M, Chan KK. Identification of thiols and benzoamides as selective and potent gastrokinetic agents. 2. Synthesis and Carcinogenesis. 2007;28:4916–22.

103. Richardson PG, Laubach JP, Lonial S, Moreau P, Yoon S-S, Hungria VT, Dimopoulos MA, Bekac S, Alizina M, San-Miguel JF. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther. 2015;15:377–84.

104. Hzenjak A, Moinfar F, Kermser M-L, Strohmeier B, Petru E, Zatloukal K, Denk H. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010;9:49.

105. Kato S, Morie T, Kon T, Yoshida N, Karasawa T, Matsumoto J. Novel protein deacetylase inhibitor, in the blood. Rapid Commun Mass Spectrom. 2002;17:757–66.

106. Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally active deacetylase inhibitor. J Med Chem. 1999;41:6616–24.

107. Hubeek I, Comijn E, Van der Wilt C, Merriman R, Padron J, Kaspers G, Peters H. Histone deacetylase genes in human cancer. J Cell Mol Med. 2008;12:2843–52.

108. Knutson SK, Warholic T, Iglesias S, Hossain GS, Kocerha J. The potential for microRNAs in clinical research. Front Genet. 2019;10:478.
139. Lee B, Mazar J, Aftab MN, Qi F, Shelley J, Li J-L, Govindarajan S, Valerio F, Rivera I, Thurn T. Long noncoding RNAs as putative biomarkers for prostate cancer detection. J Mol Diagnostics. 2014;16:615–26.

140. Gutschner T, Hämmerle M, Ellmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Groß M. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73:1180–9.

141. Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med. 2018;24:257–77.

142. West AC, Mattarollo SR, Shortt J, Cluse LA, Christiansen AJ, Smyth MJ, Johnstone RW. An intact immune system is required for the anticancer actions of histone deacetylase inhibitors. Cancer Res. 2013;73:2655–76.

143. Welsbog DS, Xu J, Chen Y, Borsul S, Scher H, Rosen N, Sawyer CL. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res. 2009;69:9586–66.

144. Shahbaz J, Liu PY, Atmadibrata B, Bradner JE, Marshall GM, Lock RB, Liu T. The bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat synergistically reduce N-Myc expression and induce anticancer effects. Clin Cancer Res. 2016;22:2534–44.

145. Harding T, Swanson J, Van Ness B. EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. Oncotarget. 2018;9:21930.

146. Zeller C, Dai W, Steele NL, Siddiqui A, Valley AJ, Wilhelm-Benartzi C, Rizzo S, Zeller C, Dai W, Steele NL, Siddiqui A, Valley AJ, Wilhelm-Benartzi C, Rizzo S. Harding T, Swanson J, Van Ness B. EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. Oncotarget. 2018;9:21930.

147. Lachenmayer A, Tofsanin S, Cabellos L, Alinret C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012;56:1343–50.

148. Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger M, Ganten MM, Gauerken G, Scheulen ME, Wiehe H. Resminostat plus sorafenib for hepatocellular carcinoma: the SHELTER study. J Hepatol. 2016;65:280–8.

149. Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, Lee B, Mazar J, Aftab MN, Qi F, Shelley J, Govindarajan S, Valerio F, Li J-L, Cruickshank S, Miller KD, Lee MJ, Trepel JB. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without letrozole in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a aromatase inhibitor. J Clin Oncol. 2013;31:2128.

150. Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA. Phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Res. 2010;70:3467–56.

151. Giannini EG, Ganten MM, Gauerken G, Scheulen ME, Wiehe H. Resminostat plus sorafenib for hepatocellular carcinoma: the SHELTER study. J Hepatol. 2016;65:280–8.

152. Miles C, Huang C, Chandrasekar M, Swanson J, Van Ness B. EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. Oncotarget. 2018;9:21930.

153. Ahn MJ, Yang JC-H, Liang J, Kang JH, Xu Q, Chen YM, Blaum J, Peng G, Linn C, Orlando M. Randomized phase II trial of first-line treatment with permetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in east Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer. 2012;77:346–52.

154. Kretzbach D, Gökküçü N, Schwartz S, Reinhardt R, Brüggenmann M, Viardot A, Walsch R, Starch M, Theil E, Hoeller D. Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia. Haematologica. 2017;102:1739–47.

155. Trottassery Jv, Sambandam V, Allan PW, Maddy JA, Maxuitenko YV, Tiwari K, Hollingshead M, Parker WB. Novel DNA methyltransferase-1 (DNMT1)– depleted anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine. Cancer Chemother Pharmacol. 2014;74:291–302.

156. Ahn MJ, Yang JC-H, Liang J, Kang JH, Xu Q, Chen YM, Blaum J, Peng G, Linn C, Orlando M. Randomized phase II trial of first-line treatment with permetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in east Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer. 2012;77:346–52.

157. Kretzbach D, Gökküçü N, Schwartz S, Reinhardt R, Brüggenmann M, Viardot A, Walsch R, Starch M, Theil E, Hoeller D. Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia. Haematologica. 2017;102:1739–47.

158. Trottassery Jv, Sambandam V, Allan PW, Maddy JA, Maxuitenko YV, Tiwari K, Hollingshead M, Parker WB. Novel DNA methyltransferase-1 (DNMT1)– depleted anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine. Cancer Chemother Pharmacol. 2014;74:291–302.
minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18:1386–96.

177. Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn L-J, van der Veer E, Raney AK, Hodges MR, Patrick AK. In vitro antiviral activity and preclinical and clinical resistance profile of miraviren, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother. 2015;59:599–608.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.